U.K. eases up on Effexor
Executive Summary
The U.K. Medicines & Healthcare products Regulatory Agency lessens restrictions for Wyeth's serotonin and norepinephrine reuptake inhibitor Effexor. New guidance narrows limitations for patients with heart problems to high-risk groups and advises specialist supervision only for doses of 300 mg or more. Previous guidance was based on evidence of increased risk of overdose-related deaths and other risks (1"The Pink Sheet" Dec. 13, 2004, p. 7)...